Information Provided By: 
Fly News Breaks for August 5, 2016
CLVS
Aug 5, 2016 | 06:44 EDT
SunTrust analyst Peter Lawson initiated Clovis with a Buy and $25 price target. The analyst said Clovis could take the lead in the treatment setting in ovarian cancer, with clinical data better than the approved PARP inhibitor. He expects the launch of rucaparib in early 2017 and Phase 3 data from the maintenance setting in 2Q17, and estimates peak sales over $250M by 2022. Lawson said as a pure play on PARP inhibitors, Clovis is well positioned for upside and as an M&A target.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
